Literature DB >> 9057660

Genetic correction of p67phox deficient chronic granulomatous disease using peripheral blood progenitor cells as a target for retrovirus mediated gene transfer.

W M Weil1, G F Linton, N Whiting-Theobald, S J Vowells, S P Rafferty, F Li, H L Malech.   

Abstract

Chronic granulomatous disease (CGD) can result from any of four single gene defects involving the components of the superoxide (O-2) generating phagocyte nicotinamide adenine dinucleotide phosphate (NADPH) oxidase. We show that transduction of peripheral blood CD34+ hematopoietic progenitors from a p67phox deficient CGD patient with replication defective amphotropic retrovirus encoding p67phox (MFGS-p67phox) significantly corrected the CGD functional defect in phagocyte oxidase activity in vitro. Using a chemiluminescence assay of oxidase activity, we showed that transduced patient CD34+ progenitors differentiating to myeloid cells in culture produced 25% of the total superoxide produced by normal CD34+ progenitors differentiating in culture. A flow cytometric assay of oxidase activity used to assess the oxidase function of individual cells in the cultures indicated that up to 32% of maturing granulocytes derived from transduced CD34+ progenitors from the p67phox CGD patient were oxidase positive with the average level of correction per granulocyte of 85% of that seen with granulocytes in similar cultures of CD34+ progenitors from normal volunteers. Nitroblue tetrazolium dye reduction assays of colonies of transduced progenitors in soft agar indicated that in some studies restoration of oxidase activity occurred in myeloid cells within 44% of granulocyte-erythrocyte-monocyte colonies, and within 28% of the combined group of granulocyte colonies/monocyte colonies/granulocyte monocyte colonies. These high correction rates were achieved without any selective regimen to enrich for transduced cells. This study provides a basis for development of gene therapy for the p67phox deficient form of CGD.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9057660

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

Review 1.  Chronic granulomatous disease.

Authors:  D Goldblatt; A J Thrasher
Journal:  Clin Exp Immunol       Date:  2000-10       Impact factor: 4.330

2.  Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease.

Authors:  H L Malech; P B Maples; N Whiting-Theobald; G F Linton; S Sekhsaria; S J Vowells; F Li; J A Miller; E DeCarlo; S M Holland; S F Leitman; C S Carter; R E Butz; E J Read; T A Fleisher; R D Schneiderman; D E Van Epps; S K Spratt; C A Maack; J A Rokovich; L K Cohen; J I Gallin
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-28       Impact factor: 11.205

3.  An AAVS1-targeted minigene platform for correction of iPSCs from all five types of chronic granulomatous disease.

Authors:  Randall K Merling; Colin L Sweeney; Jessica Chu; Aaron Bodansky; Uimook Choi; Debra Long Priel; Douglas B Kuhns; Hongmei Wang; Sam Vasilevsky; Suk See De Ravin; Thomas Winkler; Cynthia E Dunbar; Jizhong Zou; Kol A Zarember; John I Gallin; Steven M Holland; Harry L Malech
Journal:  Mol Ther       Date:  2014-10-07       Impact factor: 11.454

Review 4.  The molecular basis of chronic granulomatous disease.

Authors:  C Meischl; D Roos
Journal:  Springer Semin Immunopathol       Date:  1998

5.  Simian immunodeficiency virus lentivector corrects human X-linked chronic granulomatous disease in the NOD/SCID mouse xenograft.

Authors:  N Naumann; S S De Ravin; U Choi; M Moayeri; N Whiting-Theobald; G F Linton; Y Ikeda; H L Malech
Journal:  Gene Ther       Date:  2007-08-30       Impact factor: 5.250

Review 6.  Chronic granulomatous disease and other disorders of neutrophil function.

Authors:  N R Kamani; A J Infante
Journal:  Clin Rev Allergy Immunol       Date:  2000-10       Impact factor: 10.817

Review 7.  Genetics and immunopathology of chronic granulomatous disease.

Authors:  Marie José Stasia; Xing Jun Li
Journal:  Semin Immunopathol       Date:  2008-05-29       Impact factor: 11.759

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.